Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.

UNLABELLED: Once-monthly (50/50, 100, and 150 mg) and daily (2.5 mg; 3-year vertebral fracture risk reduction: 52%) oral ibandronate regimens were compared in 1609 women with postmenopausal osteoporosis. At least equivalent efficacy and similar safety and tolerability were shown after 1 year. INTRO...

Full description

Bibliographic Details
Main Authors:	Miller, P, McClung, MR, Macovei, L, Stakkestad, J, Luckey, M, Bonvoisin, B, Reginster, J, Recker, R, Hughes, C, Lewiecki, E, Felsenberg, D, Delmas, P, Kendler, D, Bolognese, M, Mairon, N, Cooper, C
Format:	Journal article
Language:	English
Published:	2005

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.

Similar Items